A Phase II, Multi-center, Open-label Study of AUY922 Administered IV on a Once-weekly Schedule in Patients With Advanced Non-small-cell Lung Cancer Who Have Received at Least Two Lines of Prior Chemotherapy

Cancer type: Lung cancer

Phase: II

Principal Investigator: Brunsvig Paal

Country: NO

Keywords: Norway, Oslo University Hospital, Non-small-cell lung cancer, NSCLC, HSP90, 3rd line treatment, Oslo

Status: Completed

Link to